VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Bio-Rad Laboratories, Inc. vs GSK plc
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bio-Rad Laboratories, Inc.
BIO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bio-Rad Laboratories, Inc.'s moat claims, evidence, and risks.
View BIO analysisGSK plc
GSK · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: GSK plc leads (62 / 100 vs 61 / 100 for Bio-Rad Laboratories, Inc.).
- Segment focus: Bio-Rad Laboratories, Inc. has 2 segments (59.9% in Clinical Diagnostics); GSK plc has 3 segments (37.6% in Specialty Medicines).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Bio-Rad Laboratories, Inc. has 6 moat types across 3 domains; GSK plc has 4 across 3.
Primary market context
Bio-Rad Laboratories, Inc.
Clinical Diagnostics
In vitro diagnostics test systems, reagents/test kits, informatics, and clinical laboratory quality controls
Global
Hospital laboratories; diagnostic reference laboratories; transfusion laboratories; physician office laboratories
IVD OEM / installed-base consumables supplier (systems + kits + controls)
59.9%
GSK plc
Specialty Medicines
Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)
Global
Hospitals, specialist physicians, payers
Innovator & branded manufacturer
37.6%
Side-by-side metrics
Moat coverage
Shared moat types
Bio-Rad Laboratories, Inc. strengths
GSK plc strengths
Segment mix
Bio-Rad Laboratories, Inc. segments
Full profile >Life Science
Competitive
Clinical Diagnostics
Oligopoly
GSK plc segments
Full profile >Vaccines
Oligopoly
Specialty Medicines
Oligopoly
General Medicines
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.